Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Income Statement [Abstract]        
Research and development revenue $ 944,000 $ 0 $ 1,175,000 $ 1,760,000
Grant revenue 423,000 42,000 674,000 167,000
Total revenue 1,367,000 42,000 1,849,000 1,927,000
Operating expenses:        
Research and development 7,662,000 1,240,000 14,350,000 2,307,000
General and administrative 3,718,000 2,447,000 6,627,000 4,237,000
Total operating expenses 11,380,000 3,687,000 20,977,000 6,544,000
Loss from operations 10,013,000 3,645,000 19,128,000 4,617,000
Interest and other income, net 118,000 1,000 200,000 1,000
Interest expense (98,000) (422,000) (393,000) (645,000)
Change in fair value of warrant liabilities 298,000 2,000 912,000 3,000
Net loss 9,695,000 4,064,000 18,409,000 5,258,000
Deemed dividends on preferred stock 0 392,000 0 820,000
Net loss attributable to common shareholders $ 9,695,000 $ 4,456,000 $ 18,409,000 $ 6,078,000
Net loss per share attributable to common shareholders:        
Basic and diluted $ 0.36 $ 20.76 $ 0.68 $ 28.32
Weighted average number of shares used in net loss per share calculations:        
Basic and diluted 27,062,440 214,641 27,026,263 214,641
Other comprehensive loss:        
Unrealized gain (loss) on available-for-sale securities $ 0 $ 0 $ 0 $ 0
Comprehensive loss $ 9,695,000 $ 4,456,000 $ 18,409,000 $ 6,078,000